Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06424795 · ClinicalTrials.gov registry record
Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants
A clinical trial of Respiratory Syncytial Virus Infection, sponsored by University of Rochester.
- Completed
- Registry status
- 100
- Enrollment target
- 1
- Study location
NCT06424795 is a study of Respiratory Syncytial Virus Infection that has completed, run by University of Rochester. The registered enrollment target is 100 participants, below the 983-participant average among 4 other Respiratory Syncytial Virus Infection trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06424795, a study of Respiratory Syncytial Virus Infection, has completed, sponsored by University of Rochester.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this observational study is to learn about further wheezing in infants with RSV infection.. The main question it aims to answer is: If infant factors, the infant immune response in the nose and the bacteria that reside in the nose at the time of primary RSV infection can predict/classify infants with recurrent wheezing during the following year. A secondary aim is to identify infant immune response factors in the nose and patterns of bacteria in the nose during primary RSV infection that may help us understand why recurrent wheezing occurs. Researchers will compare infants with repeated episodes of wheezing to infants who do not have further wheezing. Participants will be full term infants with their first RSV infection. We will collect information on the pregnancy and birth history as well as the signs and symptoms of RSV infection. Two nasal swabs and a nasal wash will be collected from the infants. Six weeks following the RSV infection we will begin contact with the families biweekly to determine if the infant has recurrent wheezing confirmed by a medical provider. Follow-up will continue for approximately 1 year, through a second winter season.
Conditions Studied
Study Locations (1)
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2019-12-21 |
| Est. Completion | 2024-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06424795
The ClinicalTrials.gov registry entry for NCT06424795 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 983-participant average among 4 other Respiratory Syncytial Virus Infection trials with a reported enrollment target (90% lower). The listed sponsor is University of Rochester, which has 636 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Respiratory Syncytial Virus Infection appearing as the primary indexed condition, and to 0 interventions.
NCT06424795 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06424795 about?
NCT06424795 is a clinical study titled "Molecular and Microbiome/Metagenome Correlates of Recurrent Wheeze in RSV Infected Infants". The goal of this observational study is to learn about further wheezing in infants with RSV infection.. The main question it aims to answer is: If infant factors, the infant immune response in the nose and the bacteria that reside in the nose at the time of primary RSV infection can predict/classif...
What is the current status of trial NCT06424795?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2019-12-21. Estimated completion is 2024-04-01.
What conditions does trial NCT06424795 study?
This clinical trial studies the following conditions: Respiratory Syncytial Virus Infection.
Who is sponsoring clinical trial NCT06424795?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06424795 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Syncytial Virus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
RECRUITING · Phase 2
-
The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
ACTIVE NOT RECRUITING · Phase 4
-
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract
COMPLETED · Phase 2
-
Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.